Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy

Hawtin, S; André, C; Collignon-Zipfel, G; Appenzeller, S; Bannert, B; Baumgartner, L; Beck, D; Betschart, C; Boulay, T; Brunner, HI; Ceci, M; Deane, J; Feifel, R; Ferrero, E; Kyburz, D; Lafossas, F; Loetscher, P; Merz-Stoeckle, C; Michellys, P; Nuesslein-Hildesheim, B; Raulf, F; Rush, JS; Ruzzante, G; Stein, T; Zaharevitz, S; Wieczorek, G; Siegel, R; Gergely, P; Shisha, T; Junt, T

Junt, T (通讯作者)，Novartis Pharm AG, Novartis Inst Biomed Res, CH-4056 Basel, Switzerland.

CELL REPORTS MEDICINE, 2023; 4 (5):

Abstract

Genetic and in vivo evidence suggests that aberrant recognition of RNA-containing autoantigens by Toll-like receptors (TLRs) 7 and 8 drives autoimmune......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索